PL220873B1

Uricase conjugate, pharmaceutical composition comprising thereof and the use thereof

Abstract

A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75 % of the uricolytic activity of the unmodified enzyme.

PL220873B1, drawing sheet 1 — Sheet 1 of 17

Term

Term ended

Expired 2 August 2019, 7.1 years ago.

12 claims: 1 independent, 11 dependent

1
A solution of chromatographically purified tetrameric mammalian uricase with less than 10% aggregated uricase in non-tetrameric form. 1. Roztwór chromatograficznie oczyszczonej tetramerycznej urykazy ssaczej z mniejszą niż 10% zawartością urykazy zagregowanej w postaci nietetramerycznej.

272 paragraphs in 7 sections, as filed

Description of the invention

The present invention relates to a solution of chromatographically purified tetrameric uricase.

Also described herein is the conjugation of polyethylene glycols or polyethylene oxides with urate oxidases, which substantially removes the immunogenicity of urate oxidase without reducing its uric acid-degrading activity.

Urate oxidases (uricases; EC 1.7.3.3) are enzymes that catalyze the oxidation of uric acid to a more soluble product, allantoin, a purine metabolite that is easier to remove. Man does not produce enzymatically active uricase, which is the result of a series of mutations in the uricase gene during the evolution of higher primates. Wu, X, et al., (1992) J. Mol. Evol. 34: 78-84. Consequently, in affected individuals, excessive levels of uric acid in the blood (hyperuricemia) and urine (hyperuricosuria) can lead to painful arthritis (gout), distorting amorphous urate deposits (nodules) and renal failure. For some affected individuals, available drugs such as allopurinol (a uric acid synthesis inhibitor) have side effects that limit treatment or do not adequately address symptoms. Hande, KR, et al. (1984) Am. J. Med. 76: 47-56; Fam AG, (1990) Bailliere's Clin Rheumatol 4: 177-192. Injection of uricase may, at least transiently, reduce hyperuricemia and hyperuricosuria. Since uricase is a foreign protein to humans, even the first injection of an unmodified protein from Aspergillus flavus caused anaphylactic reactions in a few percent of the treated patients (Pui, CH, et al., (1997) Leukemia 11: 1813-1816), and immune responses limited it. use for long-term or periodic treatment. Donadio, D, et al., (1981) Nouv Presse Med 10: 711-712; Leaustic. M, et al., (1983) Rev Rhum Osteoartic 50: 553-554.

For several decades, available treatments for hyperuricaemia have been considered suboptimal. Kissel, P, et al. (1968) Nature 217: 72-74. Similarly, the possibility that certain groups of patients with acute gout may benefit from a safe and effective form of injectable uricase has been recognized for many years. Davis, FF, et al. (1978) in GB Broun, et al. (Eds) Enzyme Engineering Vol. 4 (pp. 169-173) New York, Plenum Press; Nishimura, H, et al. (1979) Enzyme 24: 261-264; Nishimura, H, et al., (1981) Enzyme 26: 49-53; Davis, S, et al. (1981) Lancet 2 (8241): 281-283; Abuchowski, A. et al. (1981) J Pharmacol Exp Ther 219: 352-354; Chen, RH-L, et al., (1981) Biochim Biophys Acta 660: 293-298; Chua, CC, et al. (1988) Ann Int Med 109: 114-117; Greenberg, ML, et al. (1989) Anal Biochem 176: 290-293. Animal organ uricases are almost insoluble in solvents that are safe to inject. U.S. Patent 3,616,231. Certain uricases derived from plants or microorganisms are more soluble in medically acceptable solvents. However, injection of microbial enzymes rapidly induces immune responses that can lead to life-threatening allergic reactions or to inactivation and / or accelerated removal of uricase from the circulation. Donadio, et al., (1981); Leaustic, et al., (1983). Enzymes based on deduced amino acid sequences of uricases from mammals, such as porcine and peacock, or from insects, such as, for example, Drosophila melanogaster or Drosophila pseudoobscura (Wallrath, LL, et al., (1990) Mol Cell Biol 10: 5114-5127) are not they are useful candidates for clinical applications due to problems of immunogenicity and solubility at physiological pH.

Covalently modified poly (ethylene glycol) or poly (ethylene oxide) proteins (both referred to as PEG) have been used to increase the protein half-life and reduce immunogenicity. U.S. Patents 4,179,337, 4,766,106, and 4,847,325; Saifer, MGP, et al. (1994) Adv Exp Med Biol 366: 377-387. Attachment of high molecular weight PEG leads to conjugates with extended circulation time and / or reduced immunogenicity that retain functional activity, as previously shown for another enzyme, superoxide dismutase (Somack, R, et al. (1991) Free Rat Res Commun 12-13: 553-562; US Patents 5,283,317 and 5,468,478) and for other types of proteins e.g. cytokines (Seifer. MGP, et al., (1997) Polym Preprints 38: 576-577; Sherman. MR, et al., (1997) in JM Harris, et al. (Eds) Poly (ethylene glycol) Chemistry and Biological Applications. ACS Symposium Series 680 (pp. 155-169) Washington, DC: American Chemical Society). Conjugates of uricase with polymers other than PEG have also been described. U.S. patent 4,460,683.

In nearly all reported attempts to modify PEG uricase (e.g., covalent attachment of PEG to uricase), PEG was attached predominantly to amino groups including amino terminal residues and available lysine residues. In the most commonly used uricases,

The total number of lysine residues in each of the four identical subunits is between 25 (Aspergillus flavus (US Patent 5,382,518)) and 29 (Pig (Wu, X. et al., (1989) Proc Natl Acad Sci

USA 86: 9412-9416)). Some of the lysines in the natural conformation of the enzyme are unavailable for the PEG modification process. The most common way to reduce the immunogenicity of uricase is to attach a significant number of low molecular weight PEG chains. This has the invariable consequence of significantly reducing the enzymatic activity of the obtained conjugates.

Previously, scientists used uricase injections to catalyze the conversion of uric acid to allantoin in vivo. See Pui, et al., (1997). This is the basis for the use of Aspergillus flavus uricase (Uricozyme®) in France and Italy for the prevention or periodic correction of hyperuricemia associated with cytotoxic treatment of malignant blood diseases and for the transient reduction of acute hyperuricemia in patients with gout. Potaux, L, et al., (1975) Nouv Press Med 4: 1109-1112; Legoux, R, et al., (1992) J Biol Chem 267: 8565-8570; U.S. Patents 5,382,518 and 5,541,098. Due to its short circulation time, Uricozyme® requires daily injections. Moreover, due to its immunogenicity, it is not a preparation well suited for long-term treatment.

A single intravenous injection of the 5 kDa PEG-bound Candida utilis uricase reduced serum urate to undetectable levels in five subjects who had a pre-injection serum urate level of 6.2 mg / dL, which is within the normal range. Davis et al. (1981). Subjects were injected with additional aliquots four weeks later but their response was not reported. No anti-uricase antibodies were detected after the second (and final) injection using a relatively low-sensitivity gel diffusion assay. This report does not represent the results of long-term treatment in humans or experimental animals.

5 kDa PEG-bound uricase from Arthrobacter protoformiae has been used to temporarily control hyperuricaemia in a single patient with lymphoma who had a pre-injection serum urate level of 15 mg / dL. Chua et al. (1998). Due to the seriousness of the patient and the short duration of treatment (four injections over 14 days), it was not possible to evaluate the long-term efficacy or safety of the conjugate.

In this application, the term "immunogenic" defines the induction of an immune response by injection of a PEG-modified or unmodified (antigen) uricase preparation, while "antigenicity" defines the reaction of an antigen with pre-existing antibodies. Collectively, antigenicity and immunogenicity are referred to as "immunoreactivity". Previous studies have assessed the immunoreactivity of PEG-modified uricase by a variety of methods, including: 1) in vitro reaction of the PEG-modified uricase with previously obtained antibodies; 2) measuring the induction of antibody synthesis; and 3) accelerating the level of clearance after successive injections.

Earlier attempts to exclude the immunogenicity of uricases from multiple sources by attaching multiple PEG chains via multiple linkers have had moderate success. Modified PEG uricase was first disclosed by FF Davis and by Y Inad et al. Davis et al. (1978); U.S. Patent 4,179,337; Nishimura et al. (1979); Japanese patents 55-99189 and 62-55079. The conjugate disclosed in the '337 patent was synthesized with uricase of undetermined origin with a 2000 fold molar excess of 750 Daltons PEG, showing that a large number of polymer molecules were likely attached to each uricase molecule. The '337 patent discloses the addition of either PEG or a poly (propylene glycol) of 500 to 20,000 daltons to provide active, water-soluble, non-immunogenic conjugates of various polypeptide hormones and enzymes, including oxidoreductase. uricase was one of three examples. In addition, the '337 patent emphasizes the attachment of 10 to 100 polymer strands to the enzyme molecule and the retention of at least 40% of the enzyme activity. The experimental results regarding the degree of PEG conjugation to the available uricase amino groups, the specific uric acid-degrading activity or the immunoreactivity of the conjugate are not presented.

Data from 13 works on the modification of PEG uricase are summarized in Table 1. Some of these results are also shown graphically in Figures 1A-2B. Seven of these publications describe a significant reduction in the in vitro degrading activity of uric acid due to the attachment of a different number of PEG chains to the uricase from Candida utilis. The attachment of a large number of 5 kDa PEG chains to porcine liver uricase gave similar results as described in both Chen publications and a report by the same symposium group. Chen, et al., (1981); Davis et al. (1978).

PL 220 873 B1

Among the studies summarized in Table 1, PEG-modified uricase immunoreactivity was reduced in seven and eliminated in five of them. In three out of five subsequent studies, the elimination of immunoreactivity was accompanied by a significant reduction in the activity of degrading uric acid - 15%, 28% or 45% of the initial activity. Nishimura et al. (1979) (15% activity); Chen et al. (1981) (28% activity); Nishimura et al. (1981) (45% activity). In a subsequent report, PEG attachment was reported to 61% of the available lysine residues, but retained specific activity was not assessed. Abuchowski et al., (1981). However, research teams made up of two of the above-mentioned scientists using the same methods independently reported that over-coupling only left 23-28% of the activity. Chen et al. (1981). The 1981 publications of Abuchowski et al. And Chen et al. Show that to substantially reduce the immunogenicity of uricase, PEG must be bound to about 60% of the available lysines (Table 1). The fifth publication reporting the removal of uricase immunoreactivity did not reveal the degree of PEG attachment, the residual uric acid-degrading activity, or the nature of PEG-protein attachment. Veronese FM, et al., (1997) in JM Harris, et al., (Eds.). Poly (ethylene glycol) Chemistry and Biological Applications. ACS Symposium Series 680 (pp. 182-192) Washington DC; American Chemical Society.

PEG conjugation to a minority of uricase lysine residues limits, but does not exclude, its immunoreactivity in experimental animals. Tsuji et al. (1985) Int J Immunopharmacol 7: 725-730 (28-45% of the amino groups were coupled); Yasuda, Y, et al. (1990) Chem Pharm Bull 38: 2053-2056 (38% of the amine groups were coupled). The residual uric acid-degrading activity of the respective adducts ranged from <33% (Tsuji et al.) To 60% (Yasuda et al.) Of the baseline value. Tsuji et al., Synthesized PEG-uricase conjugates with 7.5 kDa and 10 kDa PEGs, and additionally 5 kDa PEG. All the resulting conjugates were immunogenic and antigenic in some way, while displaying limited enzymatic activity (Table 1; Figures 1A-1B).

PEGylated uricase preparations from Candida utilis that were safely administered twice were reported to each of five people as having retained only 11% of their original activity. Davis et al. (1981). Several years later, PEG-modified uricase from Arthrobacter protoformiae was administered four times to one patient with advanced lymphoma and acute hyperuricemia. Chua et al. (1988). While the residual activity of the enzyme preparation was not measured, Chua et al. indicated the absence of anti-uricase antibodies in the serum of patients 26 days after the first injection of PEG-uricase, as detected by enzyme immunoassay (ELISA).

As summarized in Table 1, previous studies on PEG-modified uricase have shown that catalytic activity is significantly reduced by attaching a sufficient number of PEG chains to substantially reduce immunoreactivity. In addition, more recent PEG-uricase preparations have been synthesized using PEG activated with cyanuric chloride, a triazine derivative (2,4,6-trichloro-1,3,5-triazine), which has been shown to introduce new antigenic determinants and initiate the formation of antibodies in rabbits. . Tsuji et al. (1985).

Table 1

Characterization of PEG-uricase from previous studies

<td>Source uricase</td><td>Tie coupling</td><td>Molecular weight of the PEG (kDa)</td><td>Percentage of PEG bound lysines</td><td>Preserved activity unfolding acid urinary (%)</td><td>Antigenicity or immunogenicity, comments</td><td>Literature</td>

<td>Not reported</td><td>azide</td><td>0.7 (diol)</td><td>No given</td><td>Not reported</td><td>Not reported</td><td>U.S. Patent 4,179,337</td>

<td>Candida utilis</td><td>Triazine chloride cyanuric</td><td> 5</td><td>% of "98": twenty 26 43 48</td><td> 31 21 15 5</td><td>Antigenicity with rabbit serum (% antigenicity of unmodified enzyme) 70% 6% 0 0</td><td>Nishimura et al., 1979</td>

Table 1 continues

<td>Candida utilis</td><td>PEG2 triazine</td><td>2 x 5</td><td> 22 25 36 46 50</td><td> 87 70 45 31 27</td><td> 86% 49% 0 0 0</td><td>Nishimura et al., 1981</td>

<td>Candida</td><td>Triazine</td><td> 5</td><td> 71</td><td> 11</td><td>Five men tolerated</td><td>Davis. et al.,</td>

<td>utilis</td><td></td><td></td><td></td><td></td><td>two injections over 30 days</td><td> 1981</td>

<td>Candida</td><td>Triazine,</td><td> 5</td><td> 49</td><td>Not reported</td><td>Immunogenicity in birds</td><td>Abuchowski</td>

<td>utilis</td><td>according to</td><td></td><td></td><td></td><td>similar to native</td><td>et al., 1981</td>

<td></td><td>Chen,</td><td></td><td></td><td></td><td>uricase</td><td></td>

<td></td><td>et al., 1981</td><td></td><td> 61</td><td>Not reported</td><td>Negative immunogenicity</td><td></td>

<td>Liver</td><td>Triazine</td><td> 5</td><td> 37</td><td> 60</td><td>Accelerated Removal</td><td>Chen, et al.,</td>

<td></td><td></td><td></td><td> 58</td><td> 28</td><td>Permanent removal</td><td></td>

<td></td><td></td><td></td><td></td><td></td><td>(half-time approx. 8 hours)</td><td></td>

<td>Candida</td><td>Triazine</td><td> 5</td><td> 57</td><td> 23</td><td>Permanent removal</td><td></td>

<td>utilis</td><td></td><td></td><td></td><td></td><td>(half-time approx. 8 hours)</td><td></td>

<td>Candida</td><td>Triazine,</td><td> 5</td><td> 35</td><td>Not reported</td><td>PEG reduces the immunogen-</td><td>Savoca, KV,</td>

<td>utilis</td><td>according to</td><td></td><td></td><td></td><td>in rabbits</td><td>et al. (1984)</td>

<td></td><td>Chen,</td><td></td><td></td><td></td><td></td><td>Int Arch Aller-</td>

<td></td><td>et al., 1981</td><td></td><td> 70</td><td>Not reported</td><td></td><td>gy App Immunol 75:</td>

<td>Candida</td><td>Triazine</td><td> 5</td><td>No</td><td>Not reported</td><td>PEG-uricase was administered</td><td>Nashida, Y,</td>

<td>utilis</td><td></td><td></td><td>given</td><td></td><td>chicken orally</td><td>et al. (1984)</td>

<td></td><td></td><td></td><td></td><td></td><td>in liposomes (once)</td><td>J Pharm</td>

<td></td><td></td><td></td><td></td><td></td><td></td><td>Pharmacol 36:</td>

<td>Candida</td><td>Triazine</td><td> 5</td><td> 44</td><td> 9,4</td><td>Limited immunogenicity</td><td>Chua, et al.,</td>

<td>utilis</td><td></td><td> 7,5</td><td> 45</td><td> 7,8</td><td>but positive in the rabbit</td><td> 1988</td>

<td></td><td></td><td> 10</td><td> 28</td><td> 32</td><td>(antibodies not for uricase,</td><td></td>

<td></td><td></td><td></td><td> 37</td><td> 11</td><td>cross-react with PEG</td><td></td>

<td></td><td></td><td></td><td> 41</td><td> 3</td><td>superoxide dismutase)</td><td></td>

<td></td><td></td><td></td><td> 45</td><td> 7,3</td><td>Antigenicity tested with mumps antibodies</td><td></td>

<td></td><td></td><td></td><td></td><td></td><td>maritime was limited</td><td></td>

<td>Arthrobacter</td><td>No</td><td> 5</td><td>No</td><td>Not reported</td><td>After 26 days from the first</td><td>Chua. et al.,</td>

<td>protoformiae</td><td>given</td><td></td><td>given</td><td></td><td>of the four injections of uricase-PEG ElISA failed to detect antibodies</td><td> 1988</td>

<td>Candida</td><td>PEG2</td><td>2 x 5</td><td> 10</td><td> 90</td><td>Not reported</td><td>Yasuda,</td>

<td>utilis</td><td>triazine</td><td></td><td> 12</td><td> 89</td><td>Not reported</td><td>et al., 1990</td>

<td></td><td></td><td></td><td> 15</td><td> 80</td><td>Not reported</td><td></td>

<td></td><td></td><td></td><td> 21</td><td> 70</td><td>Not reported</td><td></td>

<td></td><td></td><td></td><td> 38</td><td> 60</td><td>Tested antigenicity</td><td></td>

<td></td><td></td><td></td><td></td><td></td><td>rabbit serum was reduced by 75%</td><td></td>

<td>Candida</td><td>PEG2</td><td>2 x 5</td><td> 22</td><td> 68</td><td>Single injection,</td><td>Fujita. et al.,</td>

<td>utilis</td><td>triazine</td><td></td><td></td><td></td><td>PEG increases the half-life, in mice, from approx.</td><td> 1991</td>

<td></td><td></td><td></td><td></td><td></td><td>1 hour up to approx. 8 hours PEG blocks removal by</td><td></td>

<td></td><td></td><td></td><td></td><td></td><td>liver, spleen and kidneys (24-hour study period)</td><td></td>

Table 1 continues

<td>Not reported</td><td>PEG</td><td>No</td><td>No</td><td>Not reported</td><td>Immunogenicity in mice</td><td>Veronese,</td>

<td></td><td></td><td>given</td><td>given</td><td></td><td>reduced by 98% (PeG)</td><td>et al., 1997</td>

<td></td><td>PEG2</td><td></td><td>Indicated yes</td><td>Not reported</td><td></td><td></td>

<td></td><td>specified bindings</td><td></td><td>for PEG</td><td></td><td></td><td></td>

Japanese Patent 3-148298 to A Sano et al. Discloses modified proteins, including uricase, 1-12 kDa modified PEGs that exhibit antigenicity reduction and "improved, extended" performance and methods for producing such derivatized peptides. However, there is no disclosure regarding the number of chains, enzyme assays, bioassays or the meaning of the term "improved extended action". Japanese Patents 55-99189 and 62-55079, both to Y Inada, disclose uricase conjugates made using PEG-triazine or bis-PEG-triazine, respectively (referred to as PEG2 in Table 1). See Nishimura, et al., (1979 and 1981). For the first type of conjugate, the molecular weight of the PEG was 2 kDa and 5 kDa, while in the second type, only 5 kDa PEG was used. Nishimura et al. (1979) reported a recovery of 15% uricolytic activity after modification of 43% of the available 5 kDa linear PEG lysines, while Nishimura et al. (1981) reported a recovery of 31% or 45% of the uric acid-degrading activity , after modification of 46% or 36% of the lysines, respectively, with PEG2.

Previous studies reveal that when a significant reduction in uricase immunogenicity and / or antigenicity is achieved by modifying PEG, it is invariably associated with a substantial loss of uric acid-degrading activity. The safety, convenience, and cost of biopharmaceutical reagents are all negatively impacted by the reduction in potency and the consequent need for increased dosages. Consequently, there is a need for a safe and effective alternative to lower the levels of uric acid in body fluids, including blood and urine.

In a chromatographically purified tetrameric mammalian uricase solution according to the invention, less than 10%, preferably less than 5%, and more preferably less than 2% of the uricase is in non-tetrameric aggregated form. Preferably, the uricase in the solution according to the invention is porcine liver uricase, bovine liver uricase or sheep liver uricase. More preferably, the uricase in the solution of the invention is recombinant. Most preferably, the uricase in the solution of the invention is of the sequence porcine liver, bovine liver, sheep liver or baboon liver uricase or is chimeric.

When the uricase in the solution according to the invention is chimeric, it comprises portions of porcine liver uricase and baboon liver uricase. Most preferably, the chimeric uricase in the solution of the invention is a pig-baboon uricase.

In a preferred embodiment, the solution uricase according to the invention is a recombinant porcine uricase comprising lysine for arginine at position No. 291 in SEQ ID NO: 1 and serine for threonine at position 301 in SEQ ID NO: 1.

In another preferred embodiment, the solution uricase according to the invention has the sequence of baboon liver uricase in which tyrosine 97 in SEQ. ID NO: 2 was replaced with histidine.

Alternatively, the uricase in the solution of the invention comprises the amino terminus and the carboxyl terminus, and is truncated at one or both ends.

The present invention enables the production of a substantially non-immunogenic PEG-modified uricase which retains all or almost all of the uricolytic activity of the unmodified enzyme.

As indicated above, the uricase in the solution of the invention may be recombinant. Regardless of whether it is recombinant or not, the uricase in the solution of the invention is mammalian origin. The uricase can be hepatic uricase from porcine, ox, or sheep. Alternatively, the uricase in the solution of the invention may be a chimeric protein. The chimeric uricase may include a portion of porcine and / or baboon liver uricase. For example, the chimeric uricase may be a chimeric pig-baboon uricase (PBC uricase) or porcine uricase containing mutations R291K and T301S (PKS uricase) (see sequences in Fig. 6 and results of physiological and immunological studies of Figs. 7-12) . Alternatively, the uricase may be derived from baboon liver where tyosin 97 has been replaced with histidine and hence the specific activity of the uricase may be increased by at least 60%. The uricase in the solution according to the invention, irrespective of its origin, may also be in truncated form, either at the amino terminus or at the carboxyl terminus, or at both ends.

The uricase in the solution of the invention may be covalently linked to PEG in the form of PEG-uricase conjugates described below. Also described herein is a pharmaceutical composition for reducing the level of uric acid in body fluids comprising such PEG-uricase conjugates and a pharmaceutically acceptable carrier. The composition can be stabilized by lyophilization and also can be suitably diluted upon reconstitution to provide a solution useful for parenteral administration.

Also described herein is a method of reducing uric acid levels in body fluids and tissues of a mammal. The method includes administering to the mammal an amount of PEG uricase which will be effective in lowering the level of uric acid. PEG-uricase may be a purified uricase composed of two or more subunits, each subunit may be covalently linked to an average of 2 to 10 chains of a linear or branched PEG, each PEG molecule having a molecular weight between about 5 kDa and 100 kDa , in a pharmaceutically acceptable carrier. A human can be a mammal. The administration step can be, for example, intravenous, intradermal, subcutaneous, intramuscular or intraperitoneal injection, or inhalation of aerosol preparations. Elevated levels of uric acid in blood, urine, and / or other body fluids or tissues, and may be associated with gout, nodular gout, renal failure, organ transplant, or malignancy.

The uricase solution of the invention is obtained by isolating the tetrameric uricase from a solution containing the multisubunit uricase. Initially, the solution may contain tetrameric uricase or uricase aggregates. The method may include the steps of: applying the solution to at least one separation column at a pH between 9 and 10.5, for example 10.2; recovering eluate fractions and identifying those that contain the tetrameric form of uricase, which fractions are substantially free of uricase aggregates; and combinations of the isolated tetrameric uricase fractions. The separating column may be an ion exchange column, size separation or any other effective separation rule. The method may also include fraction analysis to determine the presence of uricase tetramers and / or the absence of uricase aggregates. For example, such analysis may include high performance liquid chromatography (HPLC), other chromatographic methods, light scattering, centrifugation, and / or electrophoresis. In one embodiment of the invention, the purified tetrameric uricase may contain less than about 10% uricase aggregates.

Brief description of the figures

Figure 1A shows the retention of PEG-modified uricase activity from Candida utilis as a function of the number of chains of linked PEG per subunit.

Fig. 1B shows the retention of PEG-modified uricase activity from Candida utilis as a function of the total weight of PEG attached per subunit.

Fig. 2A shows the behavior of porcine PEG-modified uricase as a function of the number of chains of linked PEG per subunit.

Figure 2B shows the behavior of porcine PEG-modified uricase as a function of the total weight of PEG attached per subunit.

Figure 3A shows the retention of PEG-modified pig-baboon uricase (PBC) activity as a function of the number of strands of attached PEG per subunit.

Fig. 3B shows the behavior of PEG-modified pig-baboon uricase (PBC) chimera as a function of total weight of attached PEG per subunit.

Fig 4A shows the retention of PEG-modified uricase activity from Aspergillus flavus as a function of the number of chains of linked PEG per subunit.

Figure 4B shows the retention of PEG-modified uricase activity from Aspergillus flavus as a function of the total weight of PEG attached per subunit.

Figure 5A shows the retention of recombinant PEG-modified soybean root uricase activity as a function of the number of chains of linked PEG per subunit.

Figure 5B shows the retention of recombinant PEG-modified soybean root uricase activity as a function of the total weight of PEG attached per subunit.

PL 220 873 B1

Figure 6 shows the deduced amino acid sequence of a chimeric porcine baboon uricase (PBC uricase), PBC uricase that is truncated at both the amino and carboxyl terminus (PBC-NT-CT), and porcine uricase containing mutations R291K and T301S (PKS uricase). compared to the pig and baboon sequences.

Figure 7 shows the activity of uricase in the serum of mice 24 hours after the administration of each of four or five intraperitoneal injections of PEG-modified PBC uricase, relative to the value obtained 24 hours after the first injection.

Figure 8 shows the inverse relationship between the activity of injected PEG-modified PBC uricase in the serum of uricase-deficient mice and the serum and urine uric acid concentrations.

Figure 9 shows the reduction in the severity of high urate syndrome in uricase-deficient (uox - / -) mice that were treated with PEG-modified PBC uricase.

Figure 10 shows the reduction in the severity of glomerular diabetes insipidus syndrome in uricase-deficient (uox - / -) mice that were treated with PEG-modified PBC uricase.

Figure 11 shows the reduction in the severity of uric acid-induced nephropathy syndrome as visualized by magnetic resonance microscopy in uricase-deficient (uox - / -) mice that were treated with PEG-modified PBC uricase.

Fig. 12 shows the accelerated clearance from the circulation of BALB / c mice of the injected PBC uricase octamer compared to the tetramer where both were bound to 5-6,000kDa by PEG chains per subunit.

Detailed Description of the Preferred Embodiments

The solution of chromatographically purified tetrameric mammalian uricase according to the invention enables the preparation of improved conjugates of water-soluble polymers, preferably polyethylene glycols or polyethylene oxides, with uricase. These conjugates are substantially non-immunogenic and retain at least 75%, preferably 85%, and most preferably 95% or more of the uric acid-degrading activity of the unmodified enzyme. Uricases useful for conjugation with water-soluble polymers include naturally occurring urate oxidases isolated from bacteria, fungi, and tissues of plants and animals, both vertebrate and invertebrate, as well as recombinant forms of uricase including mutated, hybrid and / or truncated enzymatically active variants of uricase. The water-soluble polymers described herein include linear and branched poly (ethylene glycols) or poly (ethylene oxides), all commonly known as PEG. Examples of branched PEGs are the subject of US Patent 5,643,575. One preferred example of a linear PEG is monomethoxy PEG of the general formula CH3O- (CH2CH2O) nH where n is from about 100 to about 2300.

One of the preferred mammalian uricases in the solution of the invention is a recombinant chimeric pig-baboon uricase constructed from part of the sequence of porcine liver uricase and baboon liver uricase, both of which were first identified by Wu et al., (1989). One example of such a chimeric uricase comprises the first 225 amino acids from the porcine uricase sequence (SEQ ID NO: 1) and the last 79 amino acids from the baboon uricase sequence (SEQ ID NO: 2) (pig-baboon uricase or PBC uricase; see Figure 6). Another example of such a chimeric uricase comprises residues 7-225 of the porcine sequence (SEQ ID NO: 1) and residues 226-301 of the baboon sequence (SEQ ID NO: 2); it is equivalent to PBC uricase which is truncated at both the amino and carboxyl terminus (PBC-NT-CT; see Fig. 6). Another example of such a chimeric uricase comprises the first 288 amino acids from the porcine sequence (SEQ ID NO: 1) and the last 16 amino acids from the baboon sequence (SEQ ID NO: 2). Since the last sequence differs from the porcine sequence only at two positions - with lysine (K) instead of arginine at position 291 and serine (S) instead of threonine at position 301, this mutant is referred to as pig-KS or PKS uricase. The PKS, PBC and PBC-NT-CT uricases each have one more lysine and thus one more potential site for PEG modification than both the porcine and baboon sequences. Sequences of various mammalian cDNAs for uricase, including PBC uricase, PKS uricase and baboon uricase recombinant uricase, were cloned and optimal conditions for expression determined by conventional E. coli methods. See Erlich, HA, (eds.) (1989) PCR Technology. Principles and Applications for DNA Amplification, New York: Stockton Press; Sambrook, J, et al. (1989) Molecular Cloning. A Laboratory Manual, Second Edition. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. Recombinant uricases were extracted and purified, and their stability and activity were determined using modified and standard assays. See Fridovich. I. (1965) J Biol Chem 240: 2491-2494; Nishimura et al. (1979) and Example 1.

The uricase in the solution of the invention can be conjugated via a biologically stable, non-toxic, covalent linkage to a relatively small number of PEG chains. Such linkages can include urethane (carbamate) linkages, secondary amine linkages, and amide linkages. A variety of activated PEGs suitable for this type of conjugation are commercially available from Shearwater Polymers, Hundsville, AL.

For example, urethane bonds with uricase can be generated by incubating uricase in the presence of succinimidyl carbonate (SC) or 4-nitrophenyl carbonate (NPC) modified PEG derivatives. SC-PEG can be synthesized using the procedure described in US Patent 5,612,460, which is hereby incorporated by reference. NPC-PEG can be synthesized by reacting PEG with 4-nitrophenyl chloroformate according to the methods described in Veronese, FM, et al., (1985) Appl Biochem Biotechnol 11: 141-152 and in US Patent 5,286,637, which is incorporated by reference. The methods described in the '637 patent are adapted to high molecular weight PEGs by adjusting the concentrations of the reagents to maintain a similar stoichiometry. An alternative method of synthesizing NPC-PEG is described by Biittner, W, et al. in East German Patent DD 279 486 A1.

Amide linkages with uricase can be obtained using the N-hydroxysuccinimide ester of a PEG carboxyl derivative from (Shearwater Polymers). Secondary amide linkages can be formed using 2,2,2-trifluoroethanesulfonyl PEG (tresyl PEG; Shearwater Polymers) or by reductive alkylation using PEG aldehyde (Shearwater Polymers) and cyanoborohydride.

In conjugates containing PEGs with a molecular weight between 5 kDa and 30 kDa, the maximum number of PEG chains that were attached to a subunit, while retaining at least 75% of the uric-degrading activity of the unmodified enzyme, ranged from an average of two chains for soy uricase to more than 10 strands for PBC uricase (see test conditions in Example 1 and results in Fig 1A-5B). This latter range of PEGylation corresponds to about one-third of all amino groups. The average number of PEG chains that can be attached to the uricase subunit is between 2 and 10, preferably between 3 and 8, and more preferably between 4 and 6. The molecular weight of the PEG that can be used in the attachment reaction is between kDa and 100 kDa, preferably between 10 kDa and 60 kDa, and more preferably between 20 kDa and 40 kDa, such as, for example, 30 kDa.

There are several factors that can influence the selection of the optimal molecular weight and number of PEG chains to attach to a given form of uricase. In general, reducing or eliminating immunogenicity without substantially losing the uric acid-degrading activity may require the attachment of relatively more lower molecular weight PEG chains as compared to relatively fewer higher molecular weight PEG chains. For example, either 20 kDa PEG chains per subunit or 4 30 kDa PEG chains per subunit can be optimally effective. Likewise, each different form of uricase may have a different optimum depending on the size and number of chains, see Figs. 1A-5B.

PEG conjugation makes all test uricases soluble and stable in physiological pH buffers without the need to add substrate analogs or an inhibitor such as 8-azaxanthin, which is used as a stabilizer for the fungal uricase (Uricozyme®) marketed by Sanofi Winthrop in France and Italy . Two different PBC uricase conjugates disclosed herein, one containing about 6 strands of 10 kDa PEG per subunit and the other containing about 2 strands of 19 kDa PEG per subunit. retain significant activity after incubation in mouse serum for more than one month at 37 ° C. Additionally, several of the conjugates described herein have a circulation half-life in mice greater than two days as opposed to the approximately 8 or 24 hour half-life previously reported for PEG-modified mammalian and microbial uricases. Chen et al. (1981); Fuertges, F, et al., (1990) J Contr Release 11: 139-148; Fujita, T, et al. (1991) J Pharmacobiodyn 14: 623-629. A longer half life of the injected protein drugs makes them more cost effective and can lead to improved patient compliance. The extended half-life is also characteristic of products that are better tolerated by the body.

When PEG conjugates with PBC uricase are prepared on the basis of a purified tertrameric form of the enzyme (4 subunits of 35 kDa), they reveal significantly reduced immunogenicity in mice.

(Fig. 7), in contrast to the average immunogenicity of PEG conjugates with larger forms of enzymes (35 kDa subunit octamers; see Fig. 12) and the very high immunogenicity of the unmodified enzyme. Repeated injection of PEG-uricase deficient mice with PEG-uricase disclosed herein excludes their hyperuricemia for more than two months and protects their kidney structure and function from uric acid damage (Figures 8-11).

Injection of fully active PBC uricase conjugates with 10 kDa PEG (Figs. 3A-3B) dramatically reduced hyperuricemia in homozygous uricase deficient mice (Fig. 8). Urinary uric acid levels were also reduced dramatically in all mice that were deficient in uricase and treated with PEG-modified PBC uricase. Knockout uricase mice received a series of injections of a PEG-uricase preparation similar to the one used to obtain the results in Fig. 8. This treatment reduces the severity of the effects of a urate accumulation defect as shown by measuring urate osmolality under normal conditions and after a 12 hour non-watering period (Fig. 9) and by determining water consumption and urine discharge (Fig. 10) compared to parallel measurement made in untreated genetically similar mice. It has also been shown that a 10-week treatment period, beginning in the first 10 days of life, of homozygous deficient uricase by gene knockout (uox - / -) mice with the PEG-uricase disclosed herein reduces the severity of urate-induced damage to the kidney architecture as shown by magnetic resonance microscopy (Fig. 11). For microscopic methods, see Hedlund. LW, et al. (1991) Fund Appl Toxicol 16: 787-797; Johnson. GA, et al. (1992) in JC Gore (ed.), Reviews of Magnetic Resonance in Medicine, Vol. 4 (pp. 187-219) New York: Pergamon Press.

Purified preparations of natural and recombinant uricase usually contain, in addition to the tetrameric form (140 kDa), a mixture of enzyme aggregates. The percentage of tetrameric content in each of the uricase preparations generally ranges from about 20% to 90%. Despite the data that unmodified PEG aggregates of a number of other proteins are highly immunogenic (see e.g., Moore, WV, et al., (1980) J Clin Endocrinol Metab 51: 691-697), previous PEG-uricase studies have not described any limitations in aggregate content, suggesting that the potential immunogenicity of the modified PEG aggregates was not considered. Based on the observations of the present invention, it seems likely that such aggregates were present in the enzyme preparations used for the earlier PEG-uricase syntheses. Their presence may make the goal of making non-immunogenic conjugates more difficult to achieve. It also appears that the significant loss in uric acid-degrading activity observed in earlier trials of PEG-modified uricase was dependent on the large number of low molecular weight PEG chains attached. On the other hand, the uricase purification and PEGylation methods described herein allow the covalent attachment of as many as ten PEG chains to the subunit while retaining more than 75% of the uric acid-degrading activity for at least certain uricases, e.g., chimeric pig-baboon uricase and the enzyme A flavus (see Figures 3A and 4A).

As indicated herein, substantially all aggregates of the tetrameric form of the enzyme can be removed by ion exchange or exclusion chromatography at a pH between about 9 and 10.5, preferably 10.2, prior to conjugation with PEG, resulting in a uricase preparation consisting essentially of tetramers. The molecular weight of uricase in each fraction of the preparative column can be monitored using size-differentiating analytical techniques including, for example, HPLC, conventional exclusion chromatography, centrifugation, light scattering, capillary electrophoresis, or non-denaturing buffer gel electrophoresis. During the isolation of tetrameric uricase by exclusion chromatography, only fractions containing the 140 kDa form of the enzyme can be pooled and used for PEG conjugation. For tetrameric uricase isolated by ion exchange chromatography, fractions from the ion exchange column can be analyzed for size to determine which fraction contains a significant amount of the tetrameric form without detectable aggregates. In such pooled fractions, the uricase may be at least 90% tetrameric; thus, unwanted aggregates may only make up as little as 10%, 5%, 2% or less of the total uricase isolated.

The results presented here show that the larger than tetrameric forms of PBC uricase, even with a high degree of PEG modification, are highly immunogenic in mice (Fig. 12). Moreover, in mice that were once injected with PEG conjugates of uricase aggregates, uric acid-degrading activity after sequential injection with either modified PEG tetramers or modified PEG aggregates was rapidly cleared from the circulation. Rather, conjugates are prepared

From uricase containing less than 5% aggregates, they could be injected multiple times without any acceleration of their removal rate (Fig. 7) and without detectable antibody formation as measured by enzyme immunoassay. The use of highly purified tetrameric uricase further differentiates the improved conjugates disclosed herein from the previously described PEG-uricase preparations. When comparing, the presence of a significant part (e.g. more than 10%) of aggregates in the uricase preparations used in previous studies may lead to the attachment of a large number of PEG chains to them in order to inhibit immunogenicity. As a consequence, the enzymatic activity of the obtained conjugates was significantly reduced. PEG-modified uricases in non-tetrameric forms, such as, for example, uricase dimers, are also described below, as long as preparations of such uricase conjugates retain at least about 75% of their uric acid-degrading activity and are substantially non-immunogenic.

The following examples demonstrate that the mutated baboon liver uricase shows unexpectedly increased activity relative to the non-mutated enzyme. Such improved primate uricase has been made by traditional recombinant DNA techniques. It was particularly unexpected that the single amino acid substitution (histidine for tyrosine at position 97) in baboon uricase resulted in a substantial increase in specific enzyme activity. When expressed in E. coli, this mutated protein had at least 60% higher enzymatic activity than the recombinant baboon enzyme from which it was derived.

The specific activity is increased and / or the solubility of the unmodified PEG enzyme is improved by expressing truncated variants of porcine or chimeric porcine baboon uricase of which at least the first 6 amino-terminal amino acids and / or at least 3 carboxyl-terminal amino acids are removed from the expressed protein (see Fig. 6). Recombinant uricase truncated at the carboxy terminus may be more soluble prior to PEG modification as the peroxisome targeting sequence is removed. See Miura, S, et al., (1994) Eur J Biochem 223: 141-146.

The PEG-uricase conjugates disclosed herein are useful for lowering uric acid levels in body fluids and tissues of mammals, preferably humans, and therefore may be used to treat elevated uric acid levels associated with conditions including gout, nodular gout, renal failure, organ transplant and malignant diseases. PEG-uricase conjugates can be injected into a mammal with excessive uric acid levels by any route of administration, including intravascular, subcutaneous, and intradermal. intramuscular and intraperitoneal. Alternatively, they may be nebulized and inhaled. See Patton. JS, (1996) Adv Drug Delivery Rev 19: 3-36 and Patent US 5,458,135. The effective dose of PEG-uricase will depend on the uric acid level and the size of the individual. PEG uricase may be administered with a pharmaceutically acceptable excipient or diluent in an amount ranging from about 10 µg to about 1 g. The administered amount may be between about 100 µg and 500 mg. More preferably uricase may be administered in an amount between 1 mg and 100 mg, such as, for example, 5 mg, 20 mg or 50 mg. The weights given for the dose amounts determine the amount of protein in the conjugate.

Pharmaceutical preparations containing PEG-uricase can be prepared by conventional techniques, e.g., as described in Gennaro, AR (drawing) (1990) Remington's Pharmaceutical Sciences, 18th Edition, Easton, PA: Mack Publishing Co. Useful excipients for preparing an injectable solution include, for example, phosphate buffered saline, lactated Ringer's solution, water, polyols, and glycerol. Pharmaceutical compositions for intraperitoneal administration include pharmaceutically acceptable sterile aqueous or non-aqueous liquids, dispersions, suspensions or emulsions as well as sterile powders for reconstitution, immediately before use, in sterile injectable solutions or dispersions. Such preparations may contain additional compounds such as, for example, preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, buffers, antioxidants and diluents.

PEG-uricase may also be provided as a controlled release composition for implantation into a subject to continuously control elevated levels of uric acid in body fluids. For example, polylactic acid, polyglycolic acid, regenerated collagen, poly-L-lysine, sodium alginate, gellan gum, chitosan, agarose. multi-lamellar liposomes and other traditional depots including bioerodible or biodegradable materials that can be formulated with biologically active compositions. These materials, when implanted or injected, gradually disintegrate and release active material into the surrounding tissues. For example, one method of encapsulating PEG-uricase includes the method disclosed in the US Patent

PL 220 873 B1

5,653,974, which is incorporated herein by reference. The use of bioerodible, biodegradable and other depot formulations is described herein. The use of infusion pumps and capture matrix systems to deliver PEG-uricase is also contemplated. PEG uricase may also preferably be encapsulated in micelles or liposomes. Liposome encapsulation technology is well known in the art. See e.g. Lasie, D, et al. (Eds.) (1995) Stealth Liposomes, Boca Raton, FL: CRC Press.

The PEG-uricase pharmaceutical compositions described herein will reduce the need for hemodialysis in patients at high risk of urate-induced renal failure, e.g., organ transplant recipients (see Venkataseshan, VS, et al., (1990) Nephron 56: 317-321) and patients with certain malignant diseases. In patients with significant accumulations of crystalline urate (nodules), such pharmaceutical compositions will improve quality of life faster than currently available treatments.

The following examples, which are not intended to limit the invention in any way, illustrate various aspects of the foregoing disclosure. These examples describe PEG-uricases produced by activated conjugation (e.g., electrophilic) of PEG derivatives of various sizes and compositions with naturally occurring porcine, fungal or bacterial uricase, or with recombinant soy, porcine or chimeric porcine baboon uricases. Results of activity, solubility, stability, pharmacokinetic, pharmacodynamic and immunological studies were included. The data in Figures 8-11 provide evidence for the ability of PEG-modified PBC uricase to improve hyperuricemia and hyperuricosuria and preserve kidney structure and function in an animal model in which hyperuricemia and hyperuricosuria occur causing severe kidney damage. Wu, X, et al., (1994) Proc Natl Acad Sci USA 91: 742-746. These examples provide guidance to a person of average skill in making substantially non-immunogenic uricase conjugates that retain at least about 75% of the uric acid-degrading activity of the unmodified enzyme.

Example 1

Purification of the tetramer form of uricase

The tetramer form of uricase (MW approx. 140 kDa) was purified from porcine liver uricase solution by preparative exclusion or ion exchange chromatography followed by analytical exclusion chromatography. Porcine liver uricase was obtained from Sigma-Aldrich, St. Louis, MO, Catalog No. U2350 or U3377 or from Boehringer Mannheim, Indianapolis. IN.

Preparative and analytical exclusion chromatography was performed at a pH of 10-10.5, preferably 10.2 in 10 mM sodium carbonate buffer containing 0.1 M NaCl on Superdex 200 columns, which had previously been calibrated with a protein of known molecular weight. Superdex was obtained from Amersham Pharmacia, Piscataway, NJ. Any buffer that can maintain the desired pH and that is compatible with the chemistry that will then be used to attach the PEG can be used. Such buffers are well known in the art. The ultraviolet absorbance of the preparative column eluate was monitored at 280 nm and fractions containing uricase corresponding to the molecular weight of the desired tetrameric form and free of high molecular weight species were collected for use in the synthesis of substantially non-immunogenic PEG-uricase as described in Example 2. Alternatively, the tetrameric forms of uricase may be isolated using other molecular size partitioning beds, such as, for example, Superose 12, (Amersham Pharmacia), or any other resin that is compatible with a mildly alkaline solution and exhibits a suitable size fractionation range. Such deposits are readily available and are well known in the art.

Ion exchange chromatography was performed at a pH of 10-10.5, preferably 10.2 on Mono Q columns (Amersham Pharmacia, Piscataway NJ) which had been equilibrated with 0.1 M sodium carbonate buffer. Any buffer that is compatible with the PEG coupling chemistry and that can maintain the desired pH and can be used at a sufficiently low ionic strength to allow adsorption of uricase to the column can be used. Such buffers are well known in the art. The ultraviolet absorbance of the eluate was monitored at 280 nm during the elution of the uricase from the ion exchange resin by increasing the ionic strength of the applied buffer solution e.g. a linear gradient of 0-0.5 M NaCl in sodium carbonate buffer. Size-exclusion HPLC was then used to identify fractions in the eluate containing the desired tetrameric form of uricase, without detectable aggregates, for the synthesis of substantially non-immunogenic PEG-uricase. Alternatively, the tetrameric form of the urease can be isolated with another ion exchanger support such as Q-Sepharose (Amersham Pharmacia) or any other support that is compatible with slightly alkaline solutions. Such carriers are readily available and are well known in the art.

Uricase activity was determined using a modification of the standard method. See, e.g., Fridovich (1965); Nishimura et al., (1979). Every day, freshly prepared uric acid solutions in 50 mM borate carbonate buffer, pH 9.2, were obtained to obtain concentrations for the assay of 6-150 μΜ. The uricase preparations were dissolved in a borate buffer containing bovine serum albumin (Sigma-Aldrich. St. Louis, MO, Catalog No. A-7030) such that the final albumin concentration was 0.1 mg / ml in the assay. After the various enzyme dilutions were mixed with the substrate in the wells of a microtiter plate in a plate reader, the level of uric acid decay at 25 ° C was monitored at 292 nm every 4 seconds for 3 minutes. Of the samples where between 10% and 40% of the substrate had been converted within 3 minutes, at least 20 points were used to calculate the maximum rate of absorbance decay per minute. One International Unit (IU) of uricase activity is defined as the amount of enzyme which consumes one micromole of uric acid in one minute; specific activity is expressed as IU / mg protein. Some of the relative uricase activity data reported in Figures 1A-5B was obtained in the 100 µL uric acid assay. Other results for the rate at 100 μΜ uric acid (V.100) were calculated from the value of the Michaelis constant (KM.) and maximum speed (VM.) for representative enzyme preparations, using the formula:

V100 = 100 x Vmax / (KM + 100) where Km is expressed in micromolar units.

Example 2

Attachment of PEG to tetrameric porcine uricase

To a solution of tetrameric uricase in 0.1 M sodium carbonate buffer pH 10.2, 10 - 200 moles of activated monomethoxyPEG derivative, e.g. 4-nitrophenyl carbonate (NPC-PEG) of various sizes (5 kDa to 30 kDa) for each mole were added uricase subunit (MW 35 kDa). These and other usefully activated PEGs are available from Shearwater Polymers. For instructions on attaching PEGs to proteins, see the Shearwater Polymers catalog on the Internet at www.swpolymers.com and JM Harris et al. (Eds) (1997) Poly (ethylene glycol) Chemistry and Biological Applications. ACS Symposium Series 680, Washington DC: American Chemical Society. The attachment reaction was run at 0-8 ° C until the extent of PEG coupling did not change significantly with time. Unreacted PEG was separated from the reaction products by chromatography and / or ultrafiltration.

The number of chains attached to the uricase subunit was determined using an adapted method described by Kunitani, M. et al., (1991) J Chromatogr 588: 125-137; Saifer et al. (1997) and Sherman et al. (1997). Briefly, samples of PEGylation reaction mixture or fractions from preparative ion exchange chromatography or size exclusion were characterized by analytical size exclusion HPLC on TSK 5.000 PWXL at room temperature in 10 mM sodium carbonate buffer, pH 10.2, containing 0 , 1 M NaCl. HPLC column was obtained from TosoHaas, Montgomeryville, PA. Proteins and PEGs were monitored by ultraviolet absorbance and refractive index detectors. The amount of protein in the conjugate was calculated from the ultraviolet absorbance versus the absorbance of the corresponding unmodified uricase standard. The amount of PEG in the conjugate was calculated from the refractive index peak area corrected for the contribution of the protein to the refractive index, relative to the refractive index peak area of the respective PEG standard.

Figure 2A shows the behavior of modified porcine PEG uricase as a function of the number of PEG chains attached per subunit. The inventive data (▲, □) is compared to that of Chen et al. (1981). The data in large circles refer to conjugates reported to be non-immunogenic by Chen et al. (1981). As shown in Fig. 2A, conjugates of tetrameric porcine uricase with up to 6 30 kDa PEG chains per subunit or up to 7 5 kDa PEG chains per subunit retain at least 75% of the activity of the unmodified enzyme. The observed increase in specific activity with increasing number of 5 kDa or 30 kDa PEG chains (up to 4 chains per subunit) may reflect the relative insolubility or instability of the unmodified enzyme compared to the conjugates. As shown in Fig. 2B, porcine uricase conjugates with an average of more than 3 strands of 30 kDa PEG per subunit

PEGs exhibit a greater mass of PEG than, as stated by Chen et al. (1981), is needed to sufficiently reduce immunoreactivity.

Example 3

Properties of PEG conjugates of tetrameric recombinant PBC uricase The cDNA of the recombinant chimeric pig-baboon uricase (PBC) was subcloned into the pET3d expression vector (Novagen, Madison, WI) and the obtained plasmid constructs were transformed into Escherichia coli PL21 (DE3) pLysS strain (DE3) pLysS. This procedure was performed using methods well known in the art of molecular biology. See Erlich (1989); Sambrook et al. (1989); Ausubel, F, et al. (Eds.), (1997) Short Protocols in Molecular Biology, New York: Wiley & Sons.

Figure 6 shows the deduced amino acid sequence of PBC uricase (amino acids 1-225 of SEQ ID NO: 1 and amino acids 226-304 of SEQ ID NO: 2) compared to porcine (SEQ ID NO: 1) and baboon (SEQ ID NO: 2). Amino acids in the baboon sequence that are different from that in the porcine sequence are indicated in bold. The pig and baboon sequences were first determined by Wu. et al. (1989) and confirmed by the present inventors. SEQ ID NO: 1 is identical to the sequence from GenBank Accession Number p 16164 except that the initial methionyl residue is missing in the GenBank sequence. SEQ ID NO: 2 is identical to the sequence available from GenBank under Accession Number p25689 except that the initial methionyl residue and the histidine to threonine change at position 153 in the GenBank sequence (position 154 in Figure 6) are missing.

The tetrameric form of PBC uricase was isolated and bound to PEGs of various molecular weights as described in Examples 1 and 2. Conjugates made with 5 kDa, 10 kDa, 19 kDa or 30 kDa PEG contained up to 10 PEG chains per subunit. Those made of 10 kDa PEG retained more than 95% of the original recombinant uricase specific activity (Figures 3A-3B).

The following properties of PBC tetrameric uricase conjugates with about 6 PEG chains per subunit are illustrated in the Figures given: loss of immunogenicity (Fig. 7) and efficacy in uricase-deficient mice in 1) improving hyperuricemia and hyperuricosuria (Fig. 8); 2) reducing the severity of urate accumulation defect (Fig. 9); and 3) reducing the severity of nephrogenic diabetes insipidus (Fig. 10). Additionally, PEG-uricase reduces the severity of uric acid-mediated renal destruction as visualized by magnetic resonance microscopy (Fig. 11).

Figure 7 shows the activity of PBC uricase in the serum of mice at 24 h. after each of the four or five intraperitoneal injections of PEG-uricase, based on the value obtained at 24 hours. after the first injection. PEG conjugates were made from three different preparations of PBC uricase using two different PEG activation techniques. One formulation (•) was tested in uricase deficient (uox - / -) mice; two others (Δi) were tested on normal BALB / c mice. The most immunoreactive preparation (Δ) was prepared from purified PBC uricase containing an undefined amount of uricase aggregates to which an average of 7 5 kDa PEG chains per subunit were linked using a succinimidyl carbonate (SC-PEG) modified PEG derivative. Zalipsky. Patent

US 5,612,460, incorporated by reference. Medium immunoreactive preparations () were prepared by attaching to a PBC uricase preparation containing 11% aggregates, an average of 2 PEG 19 kDa chains per subunit, using a 4-nitrophenyl carbonate (NPC-PEG) modified PEG derivative. Sherman et al. (1997). The least immunoreactive conjugate (·) was prepared by attaching an average of 6 10 kDa NPC-PEG chains per subunit to a PBC uricase preparation containing <5% uricase aggregates.

Figure 8 shows the inverse relationship between serum and urine uric acid concentration and injected PEG-uricase activity in the serum of uricase-deficient (uox - / -) mice. Injected at 0 and 72 hrs. 0.43 IU of modified PEG uricase coupled to an average of 6 PEG 10 kDa chains per enzyme subunit.

Figure 9 shows that treatment of uricase-deficient mice with PEG-modified PBC uricase reduced the severity of the urate accumulation defect. The mean and standard deviation of urine osmolality data from two mice carrying one copy of the normal mouse uricase gene (uox +/-), six untreated homozygous uricase-deficient (uox - / -) mice and six homozygous uricase-deficient mice that were between three and 72 days of age, either 95 or 190 mlU of PEG-uricase were injected ten times. Mice with any genetic background either received water ad libitum (solid bars) or were not given water for 12 hours. (dashed bars) prior to collection of urine.

PL 220 873 B1

Figure 10 shows that treatment of uricase-deficient mice with PEG-modified PBC uricase reduced the severity of nephrogenic diabetes insipidus, which is characterized by abnormally high water consumption and abnormally high urine output. The mouse genetic background and protocol were the same as in Figure 9. The mean values and standard deviation of daily water consumption (solid bars) and urination (dashed bars) are reported for the three groups of six mice.

Figure 11 shows that treatment of uricase-deficient mice with PEG-modified PBC uricase reduces the severity of uric acid-induced nephropathy as visualized by magnetic resonance microscopy. The genetic background of the three groups of mice and the treatment protocol were the same as in Figures 9 and 10. Magnetic resonance microscopy was performed at the Center for in vivo Microscopy, Duke University Medical Center, Durham, North Carolina.

In addition to the results summarized in Figures 8-11, it was shown that in all uricase-deficient mice, urinary uric acid levels decreased significantly after PBC treatment with PEG-modified uricase. Finally, Fig. 12 shows that, unlike the PEG-modified tetrameric form of PBC uricase, the octameric form (MW = 280 kDa), even if heavily modified with PEG, is immunogenic in mice. This property is reflected in the accelerated removal of the modified PEG octamer within 5 days after a single intraperitoneal injection. The same mouse was re-injected with the same dose of the PEG-uricase preparations on days 8 and 15. Twenty-four hours after the second injection, uric acid-degrading activity was undetectable in the serum of mice injected with the modified PEG octamer, but was easily detected in the serum of those injected with the PEG tetramer. This disclosure combined with the accelerated removal of the modified PEG octamer that was observed after the first injection (Fig. 12), indicates the need to remove all forms of uricase greater than the tetramer prior to modifying the PEG enzyme.

Example 4

Conjugation of uricase from Candida utilis to PEG

Uricase from Candida utilis was obtained from either Sigma-Aldrich (St. Louis, MO; Catalog No. U1878) or Worthington Biochemical Corporation (Freehold, NJ; Catalog No. URYW). Proceeding as described in Examples 1 and 2, the tetrameric form was isolated and conjugates with 5 kDa, 10 kDa or 30 kDa PEG were synthesized (Figures 1A-1B).

Figure 1A shows the retention of activity by PEG-modified uricase from Candida utilis as a function of the number of PEG chains attached per subunit. Data from the present invention (▲, ·, □) were compared with those obtained by Nishimura et al., (1979): Nishimura et al., (1981); Chen et al. (1981); Davis et al. (1981); Tsuji et al. (1985): Yasuda et al. (1990) and Fujita et al. (1991). The values in large circles refer to conjugates reported to be non-antigenic by Nishimura et al. (1979 or 1981) or by Chen et al. (1981) to be non-immunoreactive.

Figure 1B shows the retention of activity by PEG-modified uricase from Candida utilis as a function of the total weight of PEG attached per subunit. The results according to the invention (▲, ·, □) are compared with those mentioned in Fig. 1A. The values marked with large circles have the same meaning as in Fig. 1A.

As shown in Fig. 1A and Fig. 1B, conjugates with an average of up to 6 strands of 5 kDa or 30 kDa PEG or 9 strands of 10 kDa PEG per subunit retain at least 75% of the activity of the unmodified enzyme. The observed increase in specific activity with increasing number of 30 kDa PEG chains attached (up to 5 or 6 chains per subunit) may reflect the insolubility or instability of the unmodified enzyme compared to conjugates.

Example 5

PEG-conjugated uricase from Aspergillus flavus

Uricase from Aspergillus flavus was obtained from Sanofi Winthrop (Gentilly Cedex, France). Proceeding as described in Example 2, PEG conjugates of various molecular weights were synthesized (Figures 4A-4B). Conjugates were made by coupling the enzyme to A. flavus, with an average of up to 12 strands of 5 kDa PEG or up to 7 strands of 30 kDa PEG per subunit, retaining at least 15% of the initial fungal uricase activity.

Example 6

PEG conjugated soybean uricase

Recombinant soybean root nodule uricase (also called nodulin 35) was prepared and purified as described by Kahn and Tipton (Kahn, K, et al. (1997) Biochemistry 36:

PL 220 873 B1

4731-4738) and provided by Dr. Tipton (University Missouri, Columbia, MO). Proceeding as described in Examples 1 and 2, the tetrameric form was isolated and conjugates were prepared with PEGs of various molecular weights (Figures 5A-5B). In contrast to uricase from Candida utilis (Fig. 1A). porcine uricase (Fig. 2A), chimeric pig-baboon uricase (Fig. 3A) and uricase from Aspergillus flavus (Fig. 4A) The soybean enzyme only tolerated the attachment of about 2 5 kD or 30 kD PEG chains per subunit while retaining at least 75% of the initial uric acid degrading activity.

Example 7

PEG-conjugated uricase from Arthrobacter globiformis

Uricase from Arthrobacter globiformis was obtained from Sigma-Aldrich (catalog no. U 7128). See Japanese Patent 9-154581. Proceeding as described in Examples 1 and 2, the tetrameric forms were isolated and conjugates prepared with 5 kDa and 30 kDa PEGs. While conjugates with more than three 5 kDa PEG chains per subunit retained less than 60% of their initial specific activity, conjugates with an average of about two 30 kDa PEG chains per subunit retained at least 85% of their initial specific activity.

Example 8

Conjugation to PEG porcine uricase and amino-truncated PBC

Recombinant porcine uricases and PBC in which the first six amino-terminal amino acids were removed and which were expressed and purified from E. coli using standard methods as described in Example 3. The procedure was as described in Examples 1 and 2, PEG uricase truncated conjugates the amino terminus were synthesized to produce substantially non-immunogenic conjugates that retained at least 75% of the original specific activity.

Example 9

Conjugation to PEG porcine uricase and PBC truncated at the carboxy terminus or simultaneously at the amino and carboxyl terminus

Recombinant porcine uricases and PBC with at least three amino acids removed from the carboxyl terminus were expressed and purified from E. coli using standard methods as described in Example 3. Such truncation of the carboxyl terminus may increase the solubility of unmodified enzymes as the localization signal in peroxisomes. See Miura et al. (1994). Proceeding as described in Examples 1 and 2, carboxyl-truncated PEG conjugates were synthesized to generate substantially non-immunogenic conjugates that retained at least 75% of the original specific activity. The recombinant PBC uricase sequences have been shortened by six amino acids at the amino terminus and three amino acids at the carboxyl terminus (PBC-NT-CT) as shown in Figure 6. This uricase is expressed, purified, and modified with PEG as described in Examples 1, 2 and 3 to generate substantially non-immunogenic conjugates that retain at least 75% of the original specific activity.

Example 10

PEG conjugation of porcine uricase mutants containing an increased number of PEG attachment sites

Recombinant porcine uricases are prepared as described in Example 3, with the number of potential PEG attachment sites increased by replacing one or more arginine residues with lysine. See Hershfield, MS, et al., (1991) Proc Natl Acad Sci USA 88: 7185-7189. The amino acid sequence of one exemplary such mutant (PKS uricase) in which arginine at position 291 is replaced by lysine and threonine at position 301 is replaced by serine is shown in Figure 6. Proceeding as described in Examples 1 and 2, PEG was attached to uricases to produce substantially non-immunogenic conjugates that retained at least 75% of the original recombinant uricase activity.

Example 11

PEG conjugation of the recombinant baboon uricase mutant

Using standard molecular biology methods as in Example 3, a recombinant baboon uricase having an amino acid substitution (histidine for tyrosine) at position 97 was constructed (see Fig. 6). Proceeding as described in Examples 1 and 2, PEG conjugates of the tetrametic mutant form of recombinant baboon uricase are synthesized to produce conjugates of substantially limited immunogenicity that retain at least 75% of the original specific recombinant uricase activity.

PL 220 873 B1

Example 12

The immunogenicity of PEG conjugates from Candida utilis, Aspergillus flavus and Arthrobacter globiformis Uricase from Candida utilis, Aspergillus flavus and Arthrobacter globiformis is obtained as described in Examples 4, 5 and 7, respectively. Proceed as described in Examples 1 and 2, PEG conjugates are synthesized from PEG 5 kDa, 10 kDa, 20 kDa or 30 kDa. The immunogenicity of these conjugates is substantially limited or eliminated.

Sequence Listing <110> Williams, L. David

Hershfield, Michael S.

Kelly, Susan J.

Saifer, Mark GP

Sherman, Merry R.

<120> Uricase conjugate, pharmaceutical composition containing it and its use <130> MVIEW.001VPC <140>

<141>

<150> 09 / 130,392 <151> 1998 08-06 <160> 2 <170> FastSEQ for Windows version 3.0 <210> 1 <211> 304 <212> PRT <213> Sus scrofa <400> 1

<td>Val</td><td>Arg</td><td>Thr</td><td>Gly</td><td>Tyr</td><td>Gly</td><td>Lys</td><td>Asp</td><td>Underworld</td><td>How much</td><td>Lys</td><td>Val</td><td>Leu</td><td>His</td><td>How much</td><td>Gin</td>

<td>Arg</td><td>Asp</td><td>Gly</td><td>Lys</td><td>Tyr</td><td>His</td><td>Cheese</td><td>How much</td><td>Lys</td><td>Glu</td><td>Val</td><td>Ala</td><td>Thr</td><td>Cheese</td><td>Val</td><td>Gin</td>

<td>Leu</td><td>Thr</td><td>Leu</td><td>Cheese</td><td>Cheese</td><td>Lys</td><td>Lys</td><td>Asp</td><td>Tyr</td><td>Leu</td><td>His</td><td>Gly</td><td>Asp</td><td>Asn</td><td>Cheese</td><td rowspan="2">Asp</td>

<td>Phe</td><td>Lys</td><td>Gly</td><td>How much</td><td>Lys</td><td>Cheese</td><td>How much</td><td>Glu</td><td>Thr</td><td>Phe</td><td>Ala</td><td>Val</td><td>Thr</td><td>How much</td><td>Cys</td><td>Glu</td>

<td>Phe</td><td>Leu</td><td>Cheese</td><td>Cheese</td><td>Phe</td><td>Lys</td><td>His</td><td>Val</td><td>How much</td><td>Arg</td><td>Ala</td><td>Gin</td><td>Val</td><td rowspan="2">Tyr</td><td>Val</td>

<td>Gin</td><td>How much</td><td>Arg</td><td>Asn</td><td>Gly</td><td>Pro</td><td>Pro</td><td>Val</td><td>How much</td><td>His</td><td>Cheese</td><td>Gly</td><td>How much</td><td rowspan="2">Lys</td><td rowspan="2">Asp</td><td>Leu</td>

<td>Lys</td><td>Val</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Thr</td><td>Gin</td><td>Cheese</td><td>Gly</td><td>Phe</td><td>Glu</td><td>Gly</td><td>Phe</td><td>How much</td><td>Lys</td><td rowspan="2">Asp</td>

PL 220 873 B1

<td>Ala</td><td>Thr</td><td>Trp</td><td>Asp</td><td>Thr</td><td>Val</td><td>Arg</td><td>Cheese</td><td>How much</td><td>Val</td><td>Leu</td><td>Gin</td><td>Lys</td><td>Phe</td><td>Ala</td><td>Gly</td>

<td>Pro</td><td>Tyr</td><td>Asp</td><td>Lys</td><td>Gly</td><td>Glu</td><td>Tyr</td><td>Cheese</td><td>Pro</td><td>Cheese</td><td>Val</td><td>Gin</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Tyr</td>

<td>Asp</td><td>How much</td><td>Gin</td><td>Val</td><td>Leu</td><td>Thr</td><td>Leu</td><td>Gly</td><td>Gin</td><td>Val</td><td>Pro</td><td>Glu</td><td>How much</td><td>Glu</td><td>Asp</td><td>Underworld</td>

<td>Glu</td><td>How much</td><td>Cheese</td><td>Leu</td><td>Pro</td><td>Asn</td><td>How much</td><td>His</td><td>Tyr</td><td>Leu</td><td>Asn</td><td>How much</td><td>Asp</td><td>Underworld</td><td>Cheese</td><td rowspan="2">Lys</td>

<td>Underworld</td><td>Gly</td><td>Leu</td><td>How much</td><td>Asn</td><td>Lys</td><td>Glu</td><td>Glu</td><td>Val</td><td>Leu</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Asp</td><td>Asn</td><td>Pro</td>

<td>Tyr</td><td>Gly</td><td>Arg</td><td>How much</td><td>Thr</td><td>Gly</td><td>Thr</td><td>Val</td><td>Lys</td><td>Arg</td><td>Lys</td><td>Leu</td><td>Thr</td><td>Cheese</td><td>Arg</td><td>Leu</td>

<td></td><td colspan="2"> <213></td><td colspan="4">Papio hamadryas</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>

<td>Underworld</td><td>Ala</td><td>Asp</td><td>Tyr</td><td>His</td><td>Asn</td><td>Asn</td><td>Tyr</td><td>Lys</td><td>Lys</td><td>Asn</td><td>Asp</td><td>Glu</td><td>Leu</td><td>Glu</td><td>Phe</td>

<td>val</td><td>Arg</td><td>Thr</td><td>Gly</td><td>Tyr</td><td>Gly</td><td>Lys</td><td>Asp</td><td>Underworld</td><td>Val</td><td>Lys</td><td>Val</td><td>Leu</td><td>His</td><td>How much</td><td>Gin</td>

<td>Phe</td><td>Lys</td><td>Gly</td><td>How much</td><td>Lys</td><td>Cheese</td><td>How much</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Gly</td><td>Val</td><td>Asn</td><td>How much</td><td>Cys</td><td>Glu</td>

<td>Tyr</td><td>Phe</td><td>Leu</td><td>Cheese</td><td>Cheese</td><td>Phe</td><td>Asn</td><td>His</td><td>Val</td><td>How much</td><td>Arg</td><td>Ala</td><td>Gin</td><td>Val</td><td rowspan="2">Tyr</td><td>Val</td>

<td>Gin</td><td>Leu</td><td>Arg</td><td>Cheese</td><td>Gly</td><td>Pro</td><td>Pro</td><td>Val</td><td>How much</td><td>His</td><td>Cheese</td><td>Gly</td><td>How much</td><td>Lys</td><td rowspan="2">Asp</td><td>Leu</td>

<td>Pro</td><td>Tyr</td><td>Asp</td><td>Lys</td><td>Gly</td><td>Glu</td><td>Tyr</td><td>Cheese</td><td>Pro</td><td>Cheese</td><td>Val</td><td>Gin</td><td rowspan="2">Lys</td><td>Thr</td><td>Leu</td><td>Tyr</td>

<td>Asp</td><td>How much</td><td>Gin</td><td>Val</td><td>Leu</td><td>Cheese</td><td>Leu</td><td>Cheese</td><td>Arg</td><td>Val</td><td>Pro</td><td>Glu</td><td>How much</td><td>Glu</td><td>Asp</td><td>Underworld</td>

<td>Glu</td><td>How much</td><td>Cheese</td><td>Leu</td><td>Pro</td><td>Asn</td><td>How much</td><td>His</td><td>Tyr</td><td>Phe</td><td>Asn</td><td>How much</td><td>Asp</td><td>Underworld</td><td>Cheese</td><td rowspan="2">Lys</td>

<td>Tyr</td><td>Gly</td><td>Lys</td><td>How much</td><td>Thr</td><td>Gly</td><td>Thr</td><td>Val</td><td>Lys</td><td>Arg</td><td>Lys</td><td>Leu</td><td>Cheese</td><td>Cheese</td><td>Arg</td><td>Leu</td>

290 295 300

Contents7

188 members in 28 offices

This recordMember, by publication datePriority claim18 more offices are in the list below

Priority claims4

Priority claims
Document	Office	Kind	Date
13039298	United States of America	A	1998-08-06
13039298	United States of America	A	1998-08-06
09130392	–	–	–
US19980130392	–	–	–

Members188

Family members, oldest first
Document	Office	Kind
CA2338665A1	Canada	A1	2000-02-17
CA2728907A1	Canada	A1	2000-02-17
WO0007629A2	World Intellectual Property Organization (WIPO)	A2	2000-02-17
AU5251599A	Australia	A	2000-02-28
WO0007629A3	World Intellectual Property Organization (WIPO)	A3	2000-06-08
BR9912974A	Brazil	A	2001-05-08
EP1100542A2	European Patent Office (EPO)	A2	2001-05-23
CZ2001317A3	Czechia	A3	2001-07-11
KR20010072287A	Republic of Korea	A	2001-07-31
CA2398679A1	Canada	A1	2001-08-16
WO0159078A2	World Intellectual Property Organization (WIPO)	A2	2001-08-16
AU4997501A	Australia	A	2001-08-20
CN1322141A	China	A	2001-11-14
HU0103003A2	Hungary	A2	2001-11-28
HUP0103003A2	Hungary	A2	2001-11-28
PL346224A1	Poland	A1	2002-01-28
PL383331A1	Poland	A1	2002-01-28
HK1037330A1	Hong Kong, China	A1	2002-02-08
WO0159078A3	World Intellectual Property Organization (WIPO)	A3	2002-03-07
IL141220D0	Israel	D0	2002-03-10
ZA200101814B	South Africa	B	2002-05-27
JP2002522399A	Japan	A	2002-07-23
BR0108386A	Brazil	A	2002-10-29
EP1254237A2	European Patent Office (EPO)	A2	2002-11-06
KR20020087934A	Republic of Korea	A	2002-11-23
MXPA02007545A	Mexico	A	2002-12-13
CZ20022982A3	Czechia	A3	2003-01-15
IL151065D0	Israel	D0	2003-04-10
ZA200207206B	South Africa	B	2003-05-06
HU0204544A2	Hungary	A2	2003-05-28
HUP0204544A2	Hungary	A2	2003-05-28
US6576235B1	United States of America	B1	2003-06-10
CN1423699A	China	A	2003-06-11
JP2003521937A	Japan	A	2003-07-22
US2003166249A1	United States of America	A1	2003-09-04
TW570981B	Taiwan Province of China	B	2004-01-11
AU770014B2	Australia	B2	2004-02-12
HK1056742A1	Hong Kong, China	A1	2004-02-27
NZ509595A	New Zealand	A	2004-02-27
NZ520434A	New Zealand	A	2004-05-28
PL358539A1	Poland	A1	2004-08-09
US6783965B1	United States of America	B1	2004-08-31
KR20040088585A	Republic of Korea	A	2004-10-16
US2005014240A1	United States of America	A1	2005-01-20
RU2246318C2	Russian Federation	C2	2005-02-20
KR100488848B1	Republic of Korea	B1	2005-05-11
EP1100542B1	European Patent Office (EPO)	B1	2005-06-22
AT298251T	Austria	T	2005-07-15
ATE298251T1	Austria	T1	2005-07-15
RU2004104953A	Russian Federation	A	2005-07-27
DE69925917D1	Germany	D1	2005-07-28
DK1100542T3	Denmark	T3	2005-10-17
EP1588716A1	European Patent Office (EPO)	A1	2005-10-26
PT1100542E	Portugal	E	2005-11-30
ES2245114T3	Spain	T3	2005-12-16
HU0103003A3	Hungary	A3	2006-04-28
HUP0103003A3	Hungary	A3	2006-04-28
DE69925917T2	Germany	T2	2006-05-11
AU2001249975B2	Australia	B2	2006-06-08
RU2278680C2	Russian Federation	C2	2006-06-27
CN1264575C	China	C	2006-07-19
AU2006203252A1	Australia	A1	2006-08-17
RU2281954C2	Russian Federation	C2	2006-08-20
KR100614212B1	Republic of Korea	B1	2006-08-21
CN1896231A	China	A	2007-01-17
HU0204544A3	Hungary	A3	2007-05-02
HUP0204544A3	Hungary	A3	2007-05-02
KR20070092329A	Republic of Korea	A	2007-09-12
IL141220A	Israel	A	2007-09-20
RU2006107110A	Russian Federation	A	2007-09-20
RU2006107111A	Russian Federation	A	2007-09-20
IL183948D0	Israel	D0	2007-10-31
HK1103303A1	Hong Kong, China	A1	2007-12-14
US2008031864A1	United States of America	A1	2008-02-07
US2008057048A1	United States of America	A1	2008-03-06
HU226294B1	Hungary	B1	2008-08-28
KR20080098686A	Republic of Korea	A	2008-11-11
IL151065A	Israel	A	2008-12-29
IL193365D0	Israel	D0	2009-02-11
KR100884724B1	Republic of Korea	B1	2009-02-19
RU2349341C2	Russian Federation	C2	2009-03-20
TW200914617A	Taiwan Province of China	A	2009-04-01
RU2352354C2	Russian Federation	C2	2009-04-20
CN100491532C	China	C	2009-05-27
AU2006203252B2	Australia	B2	2009-06-04
AU2006203252B8	Australia	B8	2009-06-18
PL202799B1	Poland	B1	2009-07-31
AU2009212900A1	Australia	A1	2009-10-01
JP2009254376A	Japan	A	2009-11-05
EP2158923A1	European Patent Office (EPO)	A1	2010-03-03
TWI322184B	Taiwan Province of China	B	2010-03-21
EP1254237B1	European Patent Office (EPO)	B1	2010-04-07
AT463576T	Austria	T	2010-04-15
ATE463576T1	Austria	T1	2010-04-15
DE60141742D1	Germany	D1	2010-05-20
US7723089B2	United States of America	B2	2010-05-25
PT1254237E	Portugal	E	2010-06-07
CN101735991A	China	A	2010-06-16
EP2196538A1	European Patent Office (EPO)	A1	2010-06-16
DK1254237T3	Denmark	T3	2010-07-19

Showing 100 of 188

Uricase conjugate, pharmaceutical composition comprising thereof and the use thereof

Abstract

Term

PL 220 873 B1

PL 220 873 B1

PL 220 873 B1

PL 220 873 B1

PL 220 873 B1

PL 220 873 B1

PL 220 873 B1

Priority claims4

Members188

Numbers

Titles2

Classification